Tarsus Pharmaceuticals (TARS)
(Delayed Data from NSDQ)
$35.78 USD
-2.05 (-5.42%)
Updated May 22, 2024 04:00 PM ET
After-Market: $35.71 -0.07 (-0.20%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TARS 35.78 -2.05(-5.42%)
Will TARS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TARS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARS
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
Does Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect?
TARS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know
Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why
How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91%
Other News for TARS
12 Health Care Stocks Moving In Monday's Pre-Market Session
Tarsus Pharmaceuticals: A Strong Buy on Robust XDEMVY Sales and Promising Market Prospects
Tarsus Pharmaceuticals price target raised by $4 at H.C. Wainwright, here's why
Simple Ways To Stay With Trends: The Week In Charts
Tarsus Pharmaceuticals price target raised by $10 at Barclays, here's why